The FDA has suspended clinical trials at the Garden State Cancer Center until violations at the center are addressed.
The Food and Drug Administration has suspended clinical trials at the Belleville, NJ-based Garden State Cancer Center until violations at the center, documented in a Sept. 19 letter to the center's President, David Goldenberg, are addressed.
The letter cited four specific violations of FDA regulations:
•Â Failure to submit an investigational new drug application to the FDA and failure to withhold administration of an investigational new drug until an IND was in effect.
•Â Failure to ensure proper monitoring of the investigation and failure to ensure that it was conducted in accordance with the general investigational plan and protocols contained in the IND.
•Â Failure to maintain adequate records showing the receipt, shipment or other disposition of the investigational drug and failure to ensure the return of all used supplies of the investigational drug or to ensure alternative disposition of unused supplies of the investigational drug.
•Â Failure to obtain prior written approval of the FDA before charging for investigational drugs.
Goldenberg defended the cancer center and said the mistakes had all been fixed. "The cases to which the FDA letter referred all occurred before March 1995. Through that date, the center had been operating its investigational trials under the auspices of an in-house review board. When the practice came to the attention of the FDA during a routine inspection in 1995, it was agreed that all future trials would require submission of an investigational new drug application to the FDA. Since that time, every investigational trial at Garden State Cancer Center has been conducted under the auspices of an IND."
Goldenberg also characterized the FDA's alleged violations as paperwork errors and rushed to assure the Garden State Cancer Center's patients that the quality of their care was not an issue. "We believe that virtually all of the issues raised by the FDA involve paperwork and record-keeping deficiencies, not treatment," he said. "We are confident that our patients have been treated with the highest level of professionalism, safety and concern for their welfare." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.